SNX10 and glioblastoma: To evaluate the proof-of-principle therapeutic potential of SNX10 in glioblastoma, we performed SNX10 knockdown in 2 patient-derived GSCs using 3 independent shRNAs and implanted cells into the brains of immunocompromised mice.